<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201406239568N8</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2014-07-12</date_registration>
      <primary_sponsor>The Research Deputy of Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of Phenobarbital versus Morphine in the management of neonatal abstinence syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of Phenobarbital versus Morphine in the management of neonatal abstinence syndrome, a randomized controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2009-08-15</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/10133</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Neonatal Abstinence Syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Control Group:&#13;
In the randomly assigned oral morphine treatment group, initially 1 ml of a 10 mg Morphine Sulfate vial was diluted using 24 ml of distilled water, to make final concentration of 0.4 mg/ml of Morphine, then depending on the Finnegan score drug is administered in 6 divided doses / 24 hours as follow: for a Finnegan score of 8-10: 0.24 mg/kg/24hours (0.6 ml/kg/24hours), for a Finnegan score of 11-13: 0.48 mg/kg/24hours (1.2 ml/kg/24hours), for a Finnegan score of 14-16: 0.64 mg/kg/24hours (1.6 ml/kg/24hours), and for a Finnegan score of 17 and above: 0.8 mg/kg/24hours (2 ml/kg/24hours) of Morphine Sulfate is administered. These doses of Morphine Sulfate continues until Finnegan score remains below 8 for 72 hours then the drug is weaned gradually by 10% of maximal dose every day until it is entirely discontinued at the cessation dose of 0.1 mg/kg/24hours of Morphine Sulfate. Intervention 2: Intervention Group:&#13;
In the randomly assigned Phenobarbital treatment group, initially a loading dose of 20 mg/kg IV or IM is administered then if the symptoms persists another 5mg/kg is given every 8-12 hours until the entire loading dose would reach a maximum of 40 mg/kg. The maintenance dose is adjusted based on the loading dose and is initiated 12-24 hours after the last loading dose as follow: for a loading dose of 20 mg/kg the maintenance dose is 5 mg/kg/24 hours, for a loading dose of 30 mg/kg the maintenance dose is 6 mg/kg/24 hours, and for a loading dose of 40 mg/kg the maintenance dose is 8 mg/kg/24 hours administered IM or IV. These doses of Phenobarbital continued until Finnegan score remained below 8 for 72 hours then the drug is weaned gradually by 10% of maximal dose every day until it is entirely discontinued.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Mahdi Sheikh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Maternal, Fetal and Neonatal Research Center, Vali-asr Hospital, Imam Khomeini Hospital complexes, Keshavarz blvd</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733141</zip>
        <telephone>+98 912 848 1663</telephone>
        <email>mahdisheikh@gmail.com</email>
        <affiliation>Maternal, Fetal and Neonatal Research Center, Tehran University of Medical SCIENCES</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Hosein Dalili</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Maternal, Fetal and Neonatal Research Center, Vali-asr Hospital, Imam Khomeini Hospital complexes, Keshavarz blvd</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733141</zip>
        <telephone>+98 911 141 4608</telephone>
        <email>hoseindalili@yahoo.com</email>
        <affiliation>Maternal, Fetal and Neonatal Research Center, Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion Criteria:&#13;
1. neonates born at ≥ 35 weeks of gestation&#13;
2. exposure to addictive drugs in utero (determined by maternal history and positive maternal opiate screen during the last trimester of pregnancy)&#13;
3. demonstration of signs and symptoms of NAS requiring treatment (3 consecutive Finnegan score of 8 or more or 2 consecutive Finnegan score of 12 or more as calculated every 4 hours by the physician)&#13;
&#13;
Exclusion Criteria:&#13;
1. neonates born at &lt; 35 weeks of gestation&#13;
2. neonates who had intra uterine growth retardation (IUGR)&#13;
3. neonates with congenital anomalies&#13;
4. neonates with major concomitant medical illness requiring oxygen therapy, intravenous fluids or medications&#13;
5. neonates with neurologic abnormality&#13;
6. breastfed neonates&#13;
7. concomitant maternal Benzodiazepine or alcohol use&#13;
8. neonates whose parents refused to give informed consent.</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>5 days</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>P96.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Drug withdrawal syndrome in infant of dependent mother</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control Group:&#13;
In the randomly assigned oral morphine treatment group, initially 1 ml of a 10 mg Morphine Sulfate vial was diluted using 24 ml of distilled water, to make final concentration of 0.4 mg/ml of Morphine, then depending on the Finnegan score drug is administered in 6 divided doses / 24 hours as follow: for a Finnegan score of 8-10: 0.24 mg/kg/24hours (0.6 ml/kg/24hours), for a Finnegan score of 11-13: 0.48 mg/kg/24hours (1.2 ml/kg/24hours), for a Finnegan score of 14-16: 0.64 mg/kg/24hours (1.6 ml/kg/24hours), and for a Finnegan score of 17 and above: 0.8 mg/kg/24hours (2 ml/kg/24hours) of Morphine Sulfate is administered. These doses of Morphine Sulfate continues until Finnegan score remains below 8 for 72 hours then the drug is weaned gradually by 10% of maximal dose every day until it is entirely discontinued at the cessation dose of 0.1 mg/kg/24hours of Morphine Sulfate.</i_keyword>
      <i_keyword>Intervention Group:&#13;
In the randomly assigned Phenobarbital treatment group, initially a loading dose of 20 mg/kg IV or IM is administered then if the symptoms persists another 5mg/kg is given every 8-12 hours until the entire loading dose would reach a maximum of 40 mg/kg. The maintenance dose is adjusted based on the loading dose and is initiated 12-24 hours after the last loading dose as follow: for a loading dose of 20 mg/kg the maintenance dose is 5 mg/kg/24 hours, for a loading dose of 30 mg/kg the maintenance dose is 6 mg/kg/24 hours, and for a loading dose of 40 mg/kg the maintenance dose is 8 mg/kg/24 hours administered IM or IV. These doses of Phenobarbital continued until Finnegan score remained below 8 for 72 hours then the drug is weaned gradually by 10% of maximal dose every day until it is entirely discontinued.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The duration of pharmacologic treatment needed for the resolution of symptoms of NAS. Timepoint: Every 4 hours the Finnegan Score is measured by the physician till the score falls below 8. Method of measurement: Finnegan Score calculated by the physician every 4 hours.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The total duration of hospital stay. Timepoint: Measured  once at the end of hospital admission. Method of measurement: Measured based on the medical records of the neonate.</sec_outcome>
      <sec_outcome>The requirement for adjunctive therapy. Timepoint: Measured daily till the end of neonatal admission. Method of measurement: Measured based on the theraputic and medical records of the neonate.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>Maternal, Fetal and Neonatal Research Center, Tehran University of Medical Sciences</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>The Research Deputy of Tehran University of Medical Sciences</source_name>
      <source_name>Maternal, Fetal and Neonatal Research Center, Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2009-07-15</approval_date>
        <contact_name>Research Deputy and the Ethics Committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Tehran University of Medical Sciences Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
